Should You Buy CVS Health Stock Before Feb. 12?

CVS Health (NYSE: CVS) is a big name in healthcare, and it has generally been seen as a good way to invest in the industry. In addition to its pharmacy retail operations, the company has a pharmacy benefits management business. With its acquisition of Aetna in 2018, it has also become a key provider of health insurance. Despite that apparent stability, the stock hasn't been a great buy. Over the past three years, it has lost close to half of its value. And with recent management changes and many question marks surrounding the business, there's still plenty of uncertainty ahead.However, its low valuation could have investors wondering if now is the right time to take a chance on the business, especially before it releases its year-end earnings numbers on Feb. 12. Let's take a look at whether CVS could potentially be an underrated buy right now.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool